Back to map

Population: 5,440,000

Largest cities: Bratislava (capital), Kosice, Presov, Zilina

Approval Process

Slovakia was established on 1st January 1993 as the Eastern part of former Czechoslovakia. It is a EU member since 2004. The legislation has been almost fully harmonized with EU including the Drug Law.


  • realistic start-up time: 3.5 – 4 months
Recruitment Potential

With a population of approximately 5.5 million and the presence of highly qualified clinical investigators, Slovakia offers a good environment to perform clinical trials.

Slovakia is one of the EU leaders with regards to colorectal, uterine and pancreatic cancer incidence rate.

Estimated deaths per 100,000 population by cause (higher than world/European average):

Diseases Slovakia World Average Europe Average
Cardiovascular Disease 523.4 240.9 465.2
Neoplasms 225.6 222.1 236.2
Digestive Diseases 53.6 32.0 30.9
Respiratory Infections 40.7 43.6 28.9

Data from World Health Organization

Investigators and Sites

There are approximately 300 sites in Slovakia, both public and private hospitals and clinics, aproprietly equipped and offering the highest standard of treatment and diagnostic procedures. Investigators are ICH GCP experienced, well educated, motivated and deliver very high quality data.
All of the Slovak CRAs are physicians, which leads to excellent relations with the investigators and high quality of data.